Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly reports potential early assessment of antipsychotic drug response

Eli Lilly reports potential early assessment of antipsychotic drug response

10th April 2007

Eli Lilly has announced the publication of new data suggesting that the assessment of response to antipsychotic medication could be made earlier than is currently thought, with an early exhibition of non-response to treatment potentially a strong predictor of later non-response in schizophrenia patients.

Information presented to the International Congress on Schizophrenia Research (ICOSR) revealed that non-response seen as early as two weeks into treatment could strongly predict subsequent non-response, with these patients potentially benefiting from an early change in their medication regimen.

The company adds that patients with a lower subsequent symptom remission incur increased healthcare costs with while viewing medication adherence as less beneficial.

Dr John Kane, professor of psychiatry at the Albert Einstein College of Medicine in New York, said: “These data are potentially very important in helping to establish the most cost-effective strategies for treating patients with schizophrenia.”

He added that doctors are in need of improved guidelines and predictors of the response to medication from patients to assist them in making better informed decisions on effective treatment, with this study helping to meet this need.

In December 2005, Lilly reported the results of a study showing that the insistence that schizophrenia patients use generic antipsychotic medication before switching to Zyprexa (olanzapine) may not result in overall cost savings.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.